Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 204
Filtrar
1.
Drug Res (Stuttg) ; 65(12): 629-34, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25549254

RESUMO

OBJECTIVE: The lymphocyte immunosuppressant sensitivity test has been used to predict the pharmacodynamics of immunosuppressive drugs for the purpose of preventing acute rejection and infection after renal transplantation. On the other hand, measuring the ATP levels in peripheral CD4+ lymphocytes is also able to monitor the risks of rejection and infection in transplant recipients. In the present study, we examined the relationship between the mycophenolic acid pharmacodynamics and the ATP levels in peripheral lymphocytes before and after renal transplantation. METHODS: We examined both the pharmacological efficacy of mycophenolic acid and the lymphocyte ATP levels before and 2, 4 and 6 weeks after the operation in 20 renal transplant recipients. The drug's pharmacological efficacy was evaluated by the 50% inhibitory concentration of the drug against the in vitro proliferation of peripheral blood lymphocytes activated by T cell mitogen. The ATP levels in peripheral CD4+ lymphocytes were measured by the Immuknow assay kit. The relationships between the mycophenolic acid pharmacodynamics and ATP levels in peripheral lymphocytes were examined in these recipients. RESULTS: The immunosuppressive effects of mycophenolic acid against mitogen-activated lymphocyte proliferation were significantly and positively correlated with the lymphocyte ATP levels, but only at 6 weeks after transplantation. The relationship was not significant before or at 2 or 4 weeks after the operation. CONCLUSION: Our present data raised the possibility that evaluating the pharmacological efficacy of mycophenolic acid pre-transplantation and monitoring the ATP level 6 weeks after transplantation can predict the risk of rejection and/or infection in renal transplant recipients.


Assuntos
Trifosfato de Adenosina/metabolismo , Linfócitos T CD4-Positivos/efeitos dos fármacos , Linfócitos T CD4-Positivos/metabolismo , Transplante de Rim/métodos , Ativação Linfocitária/efeitos dos fármacos , Ácido Micofenólico/farmacologia , Adulto , Feminino , Humanos , Masculino , Mitógenos/antagonistas & inibidores , Adulto Jovem
2.
J Pathol ; 230(2): 228-38, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23424081

RESUMO

Fibroblast growth factors (FGFs) exert autocrine/paracrine functions in prostate cancer by stimulating angiogenesis and tumour growth. Here dihydrotestosterone (DHT) up-regulates FGF2 and FGF8b production in murine TRAMP-C2 prostate cancer cells, activating a FGF-dependent autocrine loop of stimulation. The soluble pattern recognition receptor long pentraxin-3 (PTX3) acts as a natural FGF antagonist that binds FGF2 and FGF8b via its N-terminal domain. We demonstrate that recombinant PTX3 protein and the PTX3-derived pentapeptide Ac-ARPCA-NH2 abolish the mitogenic response of murine TRAMP-C2 cells and human LNCaP prostate cancer cells to DHT and FGFs. Also, PTX3 hampers the angiogenic activity of DHT-activated TRAMP-C2 cells on the chick embryo chorioallantoic membrane (CAM). Accordingly, human PTX3 overexpression inhibits the mitogenic activity exerted by DHT or FGFs on hPTX3_TRAMP-C2 cell transfectants and their angiogenic activity. Also, hPTX3_TRAMP-C2 cells show a dramatic decrease of their angiogenic and tumourigenic potential when grafted in syngeneic or immunodeficient athymic male mice. A similar inhibitory effect is observed when TRAMP-C2 cells overexpress only the FGF-binding N-terminal PTX3 domain. In keeping with the anti-tumour activity of PTX3 in experimental prostate cancer, immunohistochemical analysis of prostate needle biopsies from primary prostate adenocarcinoma patients shows that parenchymal PTX3 expression, abundant in basal cells of normal glands, is lost in high-grade prostatic intraepithelial neoplasia and in invasive tumour areas. These results identify PTX3 as a potent FGF antagonist endowed with anti-angiogenic and anti-neoplastic activity in prostate cancer.


Assuntos
Adenocarcinoma/tratamento farmacológico , Antineoplásicos/farmacologia , Proteína C-Reativa/farmacologia , Próstata/efeitos dos fármacos , Neoplasias da Próstata/tratamento farmacológico , Componente Amiloide P Sérico/farmacologia , Adenocarcinoma/metabolismo , Adenocarcinoma/patologia , Animais , Linhagem Celular Tumoral , Embrião de Galinha , Membrana Corioalantoide/irrigação sanguínea , Membrana Corioalantoide/efeitos dos fármacos , Di-Hidrotestosterona/farmacologia , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Nus , Mitógenos/antagonistas & inibidores , Neovascularização Fisiológica/efeitos dos fármacos , Próstata/metabolismo , Próstata/patologia , Neoplasia Prostática Intraepitelial/metabolismo , Neoplasia Prostática Intraepitelial/patologia , Neoplasias da Próstata/metabolismo , Neoplasias da Próstata/patologia , Proteínas Recombinantes/farmacologia
3.
Toxicol Appl Pharmacol ; 265(1): 103-12, 2012 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-22982538

RESUMO

The caspase inhibitors, benzyloxycarbony (Cbz)-l-Val-Ala-Asp (OMe)-fluoromethylketone (z-VAD-FMK) and benzyloxycarbonyl (Cbz)-Ile-Glu (OMe)-Thr-Asp (OMe)-FMK (z-IETD-FMK) at non-toxic doses were found to be immunosuppressive and inhibit human T cell proliferation induced by mitogens and IL-2 in vitro. Both caspase inhibitors were shown to block NF-κB in activated primary T cells, but have little inhibitory effect on the secretion of IL-2 and IFN-γ during T cell activation. However, the expression of IL-2 receptor α-chain (CD25) in activated T cells was inhibited by both z-VAD-FMK and z-IETD-FMK, whereas the expression of the early activated T cell marker, CD69 was unaffected. During primary T cell activation via the antigen receptor, both caspase-8 and caspase-3 were activated and processed to their respective subunits, but neither caspase inhibitors had any effect on the processing of these two caspases. In sharp contrast both caspase inhibitors readily blocked apoptosis and the activation of caspases during FasL-induced apoptosis in activated primary T cells and Jurkat T cells. Collectively, the results demonstrate that both z-VAD-FMK and z-IETD-FMK are immunosuppressive in vitro and inhibit T cell proliferation without blocking the processing of caspase-8 and caspase-3.


Assuntos
Clorometilcetonas de Aminoácidos/farmacologia , Inibidores de Caspase/farmacologia , Imunossupressores/farmacologia , Oligopeptídeos/farmacologia , Linfócitos T/efeitos dos fármacos , Antígenos CD/biossíntese , Antígenos de Diferenciação de Linfócitos T/biossíntese , Apoptose/efeitos dos fármacos , Western Blotting , Caspase 3/metabolismo , Caspase 8/metabolismo , Proliferação de Células/efeitos dos fármacos , Separação Celular , Humanos , Indicadores e Reagentes , Interferon gama/farmacologia , Interleucina-2/antagonistas & inibidores , Interleucina-2/farmacologia , Subunidade alfa de Receptor de Interleucina-2/biossíntese , Lectinas Tipo C/biossíntese , Ativação Linfocitária/efeitos dos fármacos , Mitógenos/antagonistas & inibidores , Mitógenos/farmacologia , NF-kappa B/metabolismo , Transdução de Sinais/efeitos dos fármacos , Translocação Genética/efeitos dos fármacos , eIF-2 Quinase/metabolismo
4.
Cell Prolif ; 44(6): 516-26, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21973114

RESUMO

OBJECTIVES: Aberrant Met signalling is associated with aggressive cancer cell phenotypes. γ-tocotrienol displays potent anti-cancer activity that is associated with suppression of HER/ErbB receptor signalling. Experiments were conducted to investigate the effects of γ-tocotrienol treatment on HGF-dependent +SA mammary tumour cell proliferation, upon Met activation. MATERIALS AND METHODS: The +SA cells were maintained in serum-free defined media containing 10 ng/ml HGF as the mitogen. Cell viability was determined using the MTT assay, western blot analysis was used to measure protein expression, and Met expression and activation were determined using immunofluorescent staining. RESULTS AND CONCLUSIONS: Treatment with γ-tocotrienol or Met inhibitor, SU11274, significantly inhibited HGF-dependent +SA cell replication in a dose-responsive manner. Treatment with 4 µmγ-tocotrienol reduced both total Met levels and HGF-induced Met autophosphorylation. In contrast, similar treatment with 5.5 µm SU11274 inhibited HGF-induced Met autophosphorylation, but had no effect on total Met levels. Combined treatment with subeffective doses of γ-tocotrienol (2 µm) and SU11274 (3 µm) resulted in significant inhibition of +SA cell expansion compared to treatment with individual agents alone. These findings show, for the first time, the inhibitory effects of γ-tocotrienol on Met expression and activation, and strongly suggest that γ-tocotrienol treatment may provide significant health benefits in prevention and/or treatment of breast cancer, in women with deregulated HGF/Met signalling.


Assuntos
Antineoplásicos/farmacologia , Cromanos/farmacologia , Fator de Crescimento de Hepatócito/antagonistas & inibidores , Mitógenos/antagonistas & inibidores , Proteínas Proto-Oncogênicas c-met/antagonistas & inibidores , Vitamina E/análogos & derivados , Animais , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Ensaios de Seleção de Medicamentos Antitumorais , Feminino , Fator de Crescimento de Hepatócito/metabolismo , Indóis/farmacologia , Camundongos , Camundongos Endogâmicos BALB C , Mitógenos/metabolismo , Fosforilação , Piperazinas/farmacologia , Proteínas Proto-Oncogênicas c-met/biossíntese , Proteínas Proto-Oncogênicas c-met/metabolismo , Sulfonamidas/farmacologia , Vitamina E/farmacologia
5.
Immunobiology ; 216(6): 670-7, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21131094

RESUMO

Indian hemp is used since thousands of years as herbal drug. We found that a single dose of cannabis resin was equally active as Δ9-tetrahydrocannabinol (THC) enhancing severity and duration of symptoms in vaccinia virus infected mice. Cowpox virus did not cause symptomatic disease, but some reduction of specific antibody production was observed in drug treated animals. In vitro cannabis was superior to THC alone at inhibiting mitogen stimulated proliferation of human and mouse spleen cells and peripheral blood mononuclear cells. Also resin sub-fractions other than THC, cannabidiol and cannabinol, recovered also from cigarette smoke, were found inhibitory, suggesting additional involvement of constituents other than psychoactive THC. The immunoregulatory effects must be differentiated from apoptotic effects on spleen cells and lymphocytic mouse cell lines, which were observed with resin and THC but not with cannabidiol or cannabinol. A significant contribution of cytotoxic effects seems unlikely as drug treated lymphocytes were still capable of producing cytokines after T-cell receptor-specific stimulation. Considering a recent case of unusually severe cowpox virus infection in a young drug taker these data confirm a risk of "soft drugs" for acquiring poxvirus infection or enhancing side effects of the smallpox vaccine and perhaps also other live vaccines.


Assuntos
Canabinoides/farmacologia , Vaccinia virus/efeitos dos fármacos , Vaccinia virus/patogenicidade , Animais , Formação de Anticorpos/efeitos dos fármacos , Apoptose/efeitos dos fármacos , Linhagem Celular , Proliferação de Células/efeitos dos fármacos , Vírus da Varíola Bovina/efeitos dos fármacos , Vírus da Varíola Bovina/imunologia , Citocinas/biossíntese , Dronabinol/farmacologia , Feminino , Humanos , Leucócitos Mononucleares/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos BALB C , Mitógenos/antagonistas & inibidores , Coelhos , Receptores de Antígenos de Linfócitos T/imunologia , Receptores de Antígenos de Linfócitos T/metabolismo , Baço/efeitos dos fármacos , Baço/metabolismo , Linfócitos T/efeitos dos fármacos , Linfócitos T/imunologia , Vacínia/imunologia , Vacínia/fisiopatologia , Virulência
6.
Int Immunopharmacol ; 8(9): 1231-8, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18602069

RESUMO

Stephanotis mucronata (Blanco) Merr. has been used for rheumatoid arthritis in Chinese folk herb medicine. Guided by bioactive test, a novel potent immunosuppressive C(21) steroidal glycoside stemucronatoside K (SMK) was isolated from this plant. Its structure was elucidated on the basis of the chemical evidence and extensive spectroscopic methods. We investigated the immunosuppressive effects of SMK in vitro and in vivo. SMK significantly suppressed concanavalin A (Con A)- and lipopolysaccharide (LPS)-stimulated splenocyte proliferation in vitro in a concentration-dependent manner. ICR mice were immunized subcutaneously with OVA on the first day and administered intraperitoneally with SMK at the doses of 2.5, 5, and 10 mg/kg once daily for 10 days. At 24 h after the last administration, mitogen- and OVA-stimulated splenocyte proliferation, the levels of cytokines from splenocytes, and specific antibody titers in serum were measured. SMK significantly inhibited Con A-, LPS- and OVA-induced splenocyte proliferation in the immunized mice in a dose-dependent manner. OVA-specific IgG, IgG1, and IgG2b antibody titers were significantly reduced by SMK compared with the control group. SMK also significantly decreased OVA-induced interleukin-2 (IL-2), interferon-gamma (IFN-gamma), and IL-4 production from splenocytes in the OVA-immunized mice. These results demonstrated that SMK could suppress the cellular and humoral immune response in mice. This study provided evidence to understand the therapeutic effects of S. mucronata and an immunosuppressive natural product compound to further researches to be developed as immunosuppressant.


Assuntos
Formação de Anticorpos/efeitos dos fármacos , Apocynaceae/química , Imunidade Celular/efeitos dos fármacos , Imunossupressores , Saponinas/farmacologia , Animais , Especificidade de Anticorpos , Proliferação de Células/efeitos dos fármacos , Feminino , Imunoglobulina G/biossíntese , Imunoglobulina G/genética , Indicadores e Reagentes , Interferon gama/biossíntese , Interferon gama/genética , Interleucina-2/biossíntese , Interleucina-2/genética , Interleucina-4/biossíntese , Interleucina-4/genética , Espectroscopia de Ressonância Magnética , Camundongos , Camundongos Endogâmicos ICR , Mitógenos/antagonistas & inibidores , Mitógenos/farmacologia , Ovalbumina/imunologia , Raízes de Plantas/química , Baço/citologia , Baço/efeitos dos fármacos
7.
Stem Cells ; 26(5): 1097-108, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18308949

RESUMO

Hedgehog (Hh) signaling is involved in a wide range of important biological activities. Within the vertebrate central nervous system, Sonic Hedgehog (Shh) can act as a morphogen or mitogen that regulates the patterning, proliferation, and survival of neural stem cells (NSCs). However, its role in embryonic stem cell (ESC) neurogenesis has not been explored in detail. We have previously shown that Hh signaling is required for ESC neurogenesis. In order to elucidate the underlying mechanism, we utilized the Sox1-GFP ESC line, which has a green fluorescent protein (GFP) reporter under the control of the Sox1 gene promoter, providing an easy means of detecting NSCs in live cell culture. We show here that ESC differentiation in adherent culture follows the ESC--> primitive ectoderm --> neurectoderm transitions observed in vivo. Selective death of the Sox1-GFP-negative cells contributes to the enrichment of Sox1-GFP-positive NSCs. Interestingly, Shh is expressed exclusively by the NSCs themselves and elicits distinct downstream gene expression in Sox1-GFP-positive and -negative cells. Suppression of Hh signaling by antagonist treatment leads to different responses from these two populations as well: increased apoptosis in Sox1-GFP-positive NSCs and decreased proliferation in Sox1-GFP-negative primitive ectoderm cells. Hedgehog agonist treatment, in contrast, inhibits apoptosis and promotes proliferation of Sox1-GFP-positive NSCs. These results suggest that Hh acts as a mitogen and survival factor during early ESC neurogenesis, and evidence is presented to support a novel autocrine mechanism for Hh-mediated effects on NSC survival and proliferation.


Assuntos
Diferenciação Celular , Células-Tronco Embrionárias/citologia , Proteínas Hedgehog/metabolismo , Mitógenos/metabolismo , Neurônios/citologia , Animais , Apoptose , Comunicação Autócrina , Contagem de Células , Linhagem Celular , Proliferação de Células , Sobrevivência Celular , Proteínas de Ligação a DNA/metabolismo , Proteínas de Fluorescência Verde/metabolismo , Proteínas Hedgehog/antagonistas & inibidores , Proteínas de Grupo de Alta Mobilidade/metabolismo , Camundongos , Mitógenos/antagonistas & inibidores , Receptores Acoplados a Proteínas G/metabolismo , Fatores de Transcrição SOXB1 , Transdução de Sinais , Receptor Smoothened
8.
Vet J ; 176(3): 361-8, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17449305

RESUMO

This study examined the mitogenic response of bovine peripheral T lymphocytes to leptin, a pleiotropic hormone regulating food intake and energy expenditure. Leptin alone slightly suppressed proliferation of T lymphocytes in the presence of concanavalin A (ConA). Leptin also inhibited proliferation of T lymphocytes induced by anti-CD3 antibody. ConA treatment activated some protein kinases, including p44/p42(MAPK) and Akt/PKB, while anti-CD3 antibody treatment increased mRNA expression of suppressor of cytokine signalling (SOCS) 3, interferon (IFN)gamma, interleukin (IL) 2 and IL4 in T lymphocytes. Leptin alone increased only SOCS3 mRNA expression. Simultaneous treatment with mitogens and leptin enhanced IFNgamma mRNA expression but decreased IL2 mRNA expression, without any synergistic effect on phosphorylation of protein kinases or mRNA expression of SOCS3 and IL4. These results suggest that leptin modulates bovine T lymphocyte functions.


Assuntos
Proliferação de Células/efeitos dos fármacos , Citocinas/biossíntese , Leptina/farmacologia , Proteínas Quinases/metabolismo , Linfócitos T/citologia , Animais , Bovinos , Concanavalina A , Citocinas/genética , Citocinas/imunologia , Feminino , Ativação Linfocitária , Mitógenos/antagonistas & inibidores , Proteínas Quinases/genética , Proteínas Quinases/imunologia , Transdução de Sinais , Linfócitos T/efeitos dos fármacos
9.
Glycobiology ; 18(2): 195-204, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18065811

RESUMO

Mesenchymal stromal cells (MSC) mobilization and recruitment by experimental vascularizing tumors involves membrane type 1-matrix metalloproteinase (MT1-MMP) functions. Given that the mannose-specific lectin Concanavalin-A (ConA) induces MT1-MMP expression and mimics biological lectins/carbohydrate interactions, we synthesized and tested the potential of 11 mannoside clusters to block ConA activities on MSC. We found that tetra- and hexavalent mannosides reversed ConA-mediated changes in MSC morphology and antagonized ConA-induced caspase-3 activity and proMMP-2 activation. Tetra- and hexavalent mannosides also inhibited ConA- but not the cytoskeleton disrupting agent Cytochalasin-d-induced MT1-MMP cell surface proteolytic processing mechanisms, and effects on cell cycle phase progression. The antiproliferative and pro-apoptotic impact of ConA on the MT1-MMP/glucose-6-phosphate transporter signaling axis was also reversed by these mannosides. In conclusion, we designed and identified glycocluster constructions that efficiently interfered with carbohydrate-binding proteins (lectins) interaction with oligosaccharide moieties of glycoproteins at the cell surface of MSC. These glycoclusters may serve in carbohydrate-based anticancer strategies through their ability to specifically target MT1-MMP pleiotropic functions in cell survival, proliferation, and extracellular matrix degradation.


Assuntos
Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Células da Medula Óssea/efeitos dos fármacos , Manosídeos/farmacologia , Inibidores de Metaloproteinases de Matriz , Animais , Antineoplásicos/química , Células da Medula Óssea/citologia , Células da Medula Óssea/enzimologia , Configuração de Carboidratos , Caspase 3/metabolismo , Ciclo Celular , Proliferação de Células/efeitos dos fármacos , Concanavalina A/antagonistas & inibidores , Mananas/farmacologia , Manosídeos/química , Metaloproteinase 14 da Matriz/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Mitógenos/antagonistas & inibidores , Células Estromais/citologia , Células Estromais/efeitos dos fármacos , Células Estromais/enzimologia
10.
J Endocrinol ; 195(2): 229-40, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17951534

RESUMO

Skeletal mass is maintained by a balance between formation and resorption, cell proliferation and apoptosis. In vitro, glucocorticoids (GCs) decrease extracellular signal-regulated kinases (ERK) activation by mitogens, thus inhibiting osteoblast proliferation. Both ERK activity and proliferation are restored by co-treatment with the protein tyrosine phosphatase inhibitor, vanadate. Since ERK signalling may also be anti-apoptotic, we explored the effects of vanadate on GC-induced apoptosis in vitro and in vivo. Apoptosis in MBA-15.4 pre-osteoblasts increased from 6 h and remained up to eightfold higher through 6 days of 10(- 6) M dexamethasone (Dex) treatment. Co-incubation with 10(- 7) M vanadate markedly reduced apoptosis at all time points. Vanadate also prevented GC-induced poly-ADP-ribose polymerase cleavage. We assessed the transcriptional profiles of seven anti-apoptotic proteins (Bcl-2, Bcl-X(L), inhibitors of apoptosis protein-1 (IAP-1), IAP-2, X-linked IAP (XIAP), Fas-associated death-domain-like IL-1beta-converting enzyme-inhibitory protein (FLIP(Long)) and FLIP(Short)) in osteoblasts subjected to various stimuli using real-time quantitative PCR. Although these anti-apoptotic genes responded to different mitogenic conditions, Dex failed to repress their expression, and in fact significantly up-regulated Bcl-X(L), IAP-2 and XIAP. Dex may therefore induce apoptosis by up-regulating pro-apoptotic gene expression. We have previously demonstrated that rats treated with GC develop low formation osteoporosis (bone histomorphometry and DEXA) and skeletal fragility (breaking strength) that were largely prevented by co-treatment with vanadate. We report here that vertebrae from rats treated with 3.5 mg/kg per day methylprednisolone for 9 weeks showed increased incidence of terminal deoxynucleotidyl transferase-mediated biotin-dUTP nick end-labelling-positive apoptotic osteocytes, which was reduced by vanadate co-treatment. We conclude that vanadate prevents GC-induced apoptosis of pre-osteoblasts in vitro and osteocytes in vivo, and this may contribute to its bone-sparing effects in vivo.


Assuntos
Apoptose/efeitos dos fármacos , Dexametasona/farmacologia , Glucocorticoides/farmacologia , Osteoblastos/fisiologia , Osteócitos/fisiologia , Vanadatos/farmacologia , Animais , Apoptose/fisiologia , Células da Medula Óssea/efeitos dos fármacos , Células da Medula Óssea/fisiologia , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Sobrevivência Celular/genética , Meios de Cultura Livres de Soro/farmacologia , Expressão Gênica/efeitos dos fármacos , Glucocorticoides/antagonistas & inibidores , Peptídeos e Proteínas de Sinalização Intercelular/metabolismo , Metilprednisolona/farmacologia , Camundongos , Mitógenos/antagonistas & inibidores , Poli(ADP-Ribose) Polimerase-1 , Poli(ADP-Ribose) Polimerases/química , Poli(ADP-Ribose) Polimerases/efeitos dos fármacos , Proteínas Tirosina Fosfatases/antagonistas & inibidores , Proteínas/genética , Proteínas/fisiologia , Ratos , Ratos Sprague-Dawley , Coluna Vertebral/fisiologia , Células-Tronco/citologia , Células Estromais/efeitos dos fármacos , Células Estromais/fisiologia , Transcrição Gênica
11.
Chem Biol ; 14(4): 431-41, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17462578

RESUMO

High-mobility group box 1 protein (HMGB1) is a nuclear component, but extracellularly it serves as a signaling molecule involved in acute and chronic inflammation, for example in sepsis and arthritis. The identification of HMGB1 inhibitors is therefore of significant experimental and clinical interest. We show that glycyrrhizin, a natural anti-inflammatory and antiviral triterpene in clinical use, inhibits HMGB1 chemoattractant and mitogenic activities, and has a weak inhibitory effect on its intranuclear DNA-binding function. NMR and fluorescence studies indicate that glycyrrhizin binds directly to HMGB1 (K(d) approximately 150 microM), interacting with two shallow concave surfaces formed by the two arms of both HMG boxes. Our results explain in part the anti-inflammatory properties of glycyrrhizin, and might direct the design of new derivatives with improved HMGB1-binding properties.


Assuntos
Anti-Inflamatórios não Esteroides/metabolismo , Citocinas/antagonistas & inibidores , Ácido Glicirrízico/metabolismo , Proteína HMGB1/antagonistas & inibidores , Proteína HMGB1/metabolismo , Células 3T3 , Animais , Anti-Inflamatórios não Esteroides/química , Anti-Inflamatórios não Esteroides/farmacologia , Sítios de Ligação , Citocinas/metabolismo , DNA/metabolismo , Fluorescência , Ácido Glicirrízico/química , Ácido Glicirrízico/farmacologia , Proteína HMGB1/química , Humanos , Espectroscopia de Ressonância Magnética , Camundongos , Mitógenos/antagonistas & inibidores , Mitógenos/farmacologia , Modelos Moleculares , Ligação Proteica
12.
Immunobiology ; 211(10): 779-84, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17113915

RESUMO

Antitumor activity of a calcium-pterin suspension has been described in vitro and in animal model systems. Recent studies provide some evidence that this effect involves immune-mediated mechanisms. We investigated the influence of calcium-pterin on freshly isolated human peripheral blood mononuclear cells (PBMC) stimulated with the mitogens phytohaemagglutinin and concanavalin A in vitro. Influence of calcium-pterin on tryptophan-degrading enzyme indoleamine (2,3)-dioxygenase (IDO) and on neopterin production was monitored in supernatants of cells. Increased neopterin concentrations as well as accelerated tryptophan degradation have been found to predict poor prognosis in patients with cancer, and both these immunobiochemical pathways are induced by the pro-inflammatory cytokine interferon-gamma. Compared to unstimulated cells, mitogens induced degradation of tryptophan and formation of neopterin in PBMC, and upon addition of calcium-pterin, both biochemical results were suppressed in a dose-dependent way. Thus, calcium-pterin suppresses immunological pathways in vitro that in patients with malignant diseases characterize an unfavorable prognosis. The effect of the compound to suppress IDO activity could be of considerable relevance for the antitumoral effect of the compound because activation of the enzyme is considered as an immune-escape mechanism of tumor cells.


Assuntos
Antineoplásicos/farmacologia , Cálcio/fisiologia , Leucócitos Mononucleares/metabolismo , Neopterina/biossíntese , Pterinas/farmacologia , Triptofano/sangue , Células Cultivadas , Humanos , Leucócitos Mononucleares/efeitos dos fármacos , Mitógenos/antagonistas & inibidores , Mitógenos/farmacologia , Neopterina/antagonistas & inibidores
13.
Scand J Immunol ; 64(4): 376-81, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16970677

RESUMO

Mycoplasma mycoides ssp. mycoides biotype Small Colony (MmmSC) is the causative agent of contagious bovine pleuropneumonia (CBPP), which is still a major tropical cattle disease. Development of an efficient vaccine requires an understanding of the immunopathology of CBPP as MmmSC presents a strong ability to escape the host immune response. The objective of this study was to determine whether the presence of MmmSC can modulate the immune response induced by the mitogen Concanavalin A (ConA) on bovine immune cells [peripheral blood mononuclear cells (PBMC) and lymph node (LN) cells]. Comparative analysis of the immunomodulating properties of viable versus heat-killed MmmSC on ConA-stimulated immune cells revealed that while heat-killed MmmSC had no effect, viable MmmSC strongly depressed, in a concentration-dependent manner, the ConA mitogenic activity (blastogenesis and interferon-gamma production). Both B-cell and T-cell activation were affected with the highest impact on the CD4 T cells. The phenotypic analysis showed that the ConA-induced proliferation of CD25(+) cells was strongly reduced when co-exposed to viable MmmSC, confirming that events associated with ConA-induced cell activation were suppressed by the pathogen. This study thus demonstrated that viable MmmSC is able to inhibit the polyclonal mitogenic activity of the ConA on bovine PBMC and LN cells. This finding strongly suggests that the persistence of viable MmmSC may also thus inhibit the bovine immune response directed towards inactivated MmmSC, whether dead or in the form of antigens, also present during infection. This study confirmed that MmmSC has evolved an efficient mechanism to prevent its elimination from the host.


Assuntos
Concanavalina A/farmacologia , Terapia de Imunossupressão , Leucócitos Mononucleares/imunologia , Leucócitos Mononucleares/microbiologia , Mitógenos/farmacologia , Mycoplasma mycoides/crescimento & desenvolvimento , Animais , Bovinos , Separação Celular , Contagem de Colônia Microbiana , Temperatura Alta , Interferon gama/antagonistas & inibidores , Interferon gama/biossíntese , Ativação Linfocitária/imunologia , Mitógenos/antagonistas & inibidores , Mycoplasma mycoides/patogenicidade
14.
Prostaglandins Other Lipid Mediat ; 78(1-4): 3-13, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16303599

RESUMO

The prostanoid prostacyclin (PGI2) inhibits proliferation of cultured vascular SMCs by inhibiting cell cycle progression from G1 to S phase. Progression through G1 phase is regulated by the sequential activation of the G1 phase cyclin-dependent kinases (cdks). Recent studies have shown that PGI2-dependent activation of its receptor, IP, inhibits G1 phase progression by blocking the degradation of p27 and the activation of cyclin E-cdk2. High Density Lipoproteins (HDL) and its associated apolipoprotein, ApoE, also inhibit S phase entry of vascular SMCs, and the effects of HDL and ApoE are, at least in part, also mediated by the production of PGI2. The antimitogenic effects of hyaluronan may also be controlled by PGI2. This review summarizes the effects of PGI2 on the G1 phase cyclin-cdks and discusses the potential role of PGI2 as a common component of multiple extracellular signals that attenuate the proliferation of vascular SMCs.


Assuntos
Quinases Ciclina-Dependentes/metabolismo , Fase G1 , Mitógenos/antagonistas & inibidores , Mitose/efeitos dos fármacos , Ciclina A/genética , Estrogênios/farmacologia , Humanos , Receptores de Hialuronatos/farmacologia , Ácido Hialurônico/farmacologia , Fosforilação , Proteínas Quinases Associadas a Fase S/genética
15.
DNA Cell Biol ; 24(10): 624-33, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16225393

RESUMO

Hepatocyte growth factor (HGF), a multifunctional cytokine, can act on many cell types. It is involved in cancer growth and metastasis by enhancing the motility of cancer cells and stimulating angiogenesis. The development of effective inhibitors for HGF is an important issue in cancer therapy. In this study, we isolated DNA aptamers against human HGF using the systematic evolution of ligands by exponential enrichment method. The selected DNA aptamers had a highly conserved consensus sequence, and could be divided into two major classes (classes I and II). The consensus motif of classes I and II might contribute to the formation of a hairpin loop structure and a G-quartet structure, respectively. These DNA aptamers bound to human HGF with high affinity and specificity. The dissociation constants of typical aptamers H38-15 and H38-21, representative of the two classes, were calculated to be approximately 20 nM. H38-15 and H38-21 inhibited the biological activities of HGF including the stimulation of scattering, migration, and invasion of pancreatic cancer KP-3 cells. Furthermore, both aptamers inhibited HGF-induced tube formation by human umbilical vein endothelial cells. These results suggested that the isolated DNA aptamers will be useful as therapeutic and diagnostic reagents for cancers.


Assuntos
Movimento Celular/efeitos dos fármacos , DNA/farmacologia , Fator de Crescimento de Hepatócito/antagonistas & inibidores , Mitógenos/antagonistas & inibidores , Neoplasias Pancreáticas/tratamento farmacológico , Sequência de Bases , Células Cultivadas , Endotélio Vascular/citologia , Endotélio Vascular/efeitos dos fármacos , Endotélio Vascular/metabolismo , Fator de Crescimento de Hepatócito/genética , Humanos , Ligantes , Mitógenos/genética , Dados de Sequência Molecular , Invasividade Neoplásica , Neovascularização Patológica/tratamento farmacológico , Neoplasias Pancreáticas/metabolismo , Neoplasias Pancreáticas/patologia , Homologia de Sequência do Ácido Nucleico , Veias Umbilicais/citologia , Veias Umbilicais/efeitos dos fármacos , Veias Umbilicais/metabolismo
16.
Semin Cell Dev Biol ; 16(3): 369-81, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15840445

RESUMO

Genetic links between deregulation of the cell cycle and cancer are well established. There have been significant recent developments both in our understanding of the molecular mechanisms that control cell cycle progression and in methods for protein structure determination at atomic resolution. These advances have allowed the rational design of small molecules that modulate the cell cycle by competing for sites of protein-protein or protein-ATP interactions. There is considerable optimism that these compounds, a selection of which are here reviewed, will become clinically significant drugs.


Assuntos
Antineoplásicos/farmacologia , Ciclo Celular/efeitos dos fármacos , Mitógenos/antagonistas & inibidores , Animais , Camundongos , Modelos Moleculares , Proteínas Nucleares/metabolismo , Ligação Proteica , Proteínas Proto-Oncogênicas/metabolismo , Proteínas Proto-Oncogênicas c-mdm2 , Transdução de Sinais/efeitos dos fármacos , Proteína Supressora de Tumor p53/metabolismo
17.
Int J Tissue React ; 27(4): 197-202, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16440585

RESUMO

Pigment epithelium-derived factor (PEDF) is a natural extracellular component of the retina with neuronal differentiating activity. Decreased levels of PEDF in the mammalian eye have been shown to participate in proliferative diabetic retinopathy. In addition, we have recently found in in vitro experiments that PEDF protected against pericyte apoptosis, the earliest histopathological hallmark of diabetic retinopathy. These observations suggest that the loss of PEDF in the mammalian eye plays an important role in the development and progression of diabetic retinopathy. However, the functional role of endothelial cell (EC)-derived PEDF in pericyte survival and the regulation of PEDF gene expression remain to be elucidated. In this study, we examined the effects of anti-PEDF antibody (Ab) on the viable cell number of cocultured pericytes with microvascular ECs. We further studied the effects of angiotensin II (Ang II) on PEDF gene expression in ECs. Anti-PEDF Ab significantly inhibited the growth-stimulating effects of cocultured ECs on pericytes. Furthermore, Ang II significantly decreased PEDF mRNA levels in ECs, which was completely reversed by an Ang II type 1 receptor blocker, telmisartan. Our present results suggest that PEDF is an EC-derived mitogen or survival factor for retinal pericytes. Suppression by Ang II of the EC-derived PEDF may be involved in exacerbation of diabetic retinopathy in patients with hypertension.


Assuntos
Angiotensina II/farmacologia , Retinopatia Diabética/metabolismo , Regulação para Baixo , Endotélio Vascular/metabolismo , Proteínas do Olho/antagonistas & inibidores , Proteínas do Olho/metabolismo , Mitógenos/metabolismo , Fatores de Crescimento Neural/antagonistas & inibidores , Fatores de Crescimento Neural/metabolismo , Pericitos/fisiologia , Serpinas/metabolismo , Adulto , Anticorpos Bloqueadores/farmacologia , Sobrevivência Celular/imunologia , Células Cultivadas , Técnicas de Cocultura , Retinopatia Diabética/patologia , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/genética , Regulação para Baixo/imunologia , Proteínas do Olho/genética , Proteínas do Olho/imunologia , Inibidores do Crescimento/farmacologia , Humanos , Microcirculação/citologia , Microcirculação/metabolismo , Mitógenos/antagonistas & inibidores , Mitógenos/genética , Mitógenos/imunologia , Fatores de Crescimento Neural/genética , Fatores de Crescimento Neural/imunologia , Pericitos/citologia , Pericitos/imunologia , RNA Mensageiro/antagonistas & inibidores , RNA Mensageiro/metabolismo , Serpinas/genética , Serpinas/imunologia
18.
Gan To Kagaku Ryoho ; 31(11): 1777-9, 2004 Oct.
Artigo em Japonês | MEDLINE | ID: mdl-15553712

RESUMO

NK4 suppresses invasion and metastasis of tumor cells by means of dual actions as HGF antagonist and angiogenesis inhibitor. Our previous studies showed that NK4 suppresses the implantation of tumor cells to the peritoneal milky spots (MS) by intraperitoneal injection (i.p.) of adenovirus vector expressing NK4 (Ad-NK4) or NK4 gene-transfected tumor cells. In the present study, we investigated the antitumor mechanisms of NK4 in the suppression of peritoneal implantation. When evaluated by a fluorescent microscopy, a prior injection of Ad-NK4 suppressed peritoneal implantation immediately after the injection of GFP-expressing tumor cells. DNA microarray analyses also demonstrated a reduced expression of some adhesion molecules in NK4 gene-transfected tumor cells as compared to neomycin gene-trasfected cells (control). In the in vitro adhesion assay, the adhesion to some types of the extra cellular matrixs (ECM) was significantly decreased in NK4 gene-transfected cells as compared to the control. These results suggest that NK4 may suppress peritoneal implantation by inhibiting adhesion of tumor cells to ECM around MS.


Assuntos
Inibidores da Angiogênese/farmacologia , Fator de Crescimento de Hepatócito/antagonistas & inibidores , Fator de Crescimento de Hepatócito/farmacologia , Mitógenos/antagonistas & inibidores , Mitógenos/farmacologia , Neoplasias Peritoneais/prevenção & controle , Neoplasias Peritoneais/secundário , Adenoviridae , Inibidores da Angiogênese/uso terapêutico , Animais , Moléculas de Adesão Celular/análise , Vetores Genéticos , Fator de Crescimento de Hepatócito/genética , Fator de Crescimento de Hepatócito/uso terapêutico , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Mitógenos/genética , Mitógenos/uso terapêutico , Inoculação de Neoplasia , Análise de Sequência com Séries de Oligonucleotídeos
19.
Transplantation ; 78(6): 831-8, 2004 Sep 27.
Artigo em Inglês | MEDLINE | ID: mdl-15385801

RESUMO

BACKGROUND: We evaluated the in vitro and in vivo immunosuppressive effects of baohuoside-1 (B1), a novel flavonoid isolated from Epimedium davidii. METHODS: Proliferation assay was used to determine the antiproliferative properties on T-cell and B-cell proliferation. Flow cytometry analysis was applied to detect changes of phenotypes on activated cells. RESULTS: B1 inhibits the lymphocyte proliferation activated by polyclonal mitogens and mixed lymphocyte reaction with a 50% inhibitory concentration of low micromolar concentration. Also, B1 suppressed T-cell activation in T cell receptor/CD3-mediated signaling pathways in a dose- and time-dependent manner. The suppression of B1 was not simply a result of a toxic effect and was recovered by withdrawing the drug. B1 down-regulated the expression of some phenotype molecules. In Ca(2+)-independent or -dependent antigen stimulation, although B1 had different inhibitive patterns on CD69 expression stimulated by phorbol 12-myristate 13-acetate (PMA) or Ca2+ ionophore, it inhibited T-cell proliferation induced by CD3/CD28 or PMA/ionomycin and partially blocked that induced by PMA/CD28. Interestingly, an additive inhibition between B1 and tacrolimus (FK506) was found in the CD69 expression stimulated by PMA/CD28 and PMA/ionomycin. Similarly, this immunosuppression by combination therapy was observed in a heart transplantation model in vivo and might act through an immunosuppressive mechanism different from FK506. CONCLUSIONS: B1, whose mechanism of action is not similar to that of FK506, has selectively immunosuppressive effects on T-cell and B-cell activation in vitro and effectively prevents rat heart allograft rejection in vivo.


Assuntos
Medicamentos de Ervas Chinesas/farmacologia , Flavonoides/farmacologia , Imunossupressores/farmacologia , Ativação Linfocitária/efeitos dos fármacos , Animais , Divisão Celular/efeitos dos fármacos , Humanos , Técnicas In Vitro , Cinética , Teste de Cultura Mista de Linfócitos , Masculino , Mitógenos/antagonistas & inibidores , Mitógenos/farmacologia , Ratos , Ratos Endogâmicos Lew , Acetato de Tetradecanoilforbol/farmacologia
20.
Oncogene ; 23(42): 7095-103, 2004 Sep 16.
Artigo em Inglês | MEDLINE | ID: mdl-15258566

RESUMO

AKAP12/Gravin, one of the A-kinase anchoring proteins (AKAPs), functions as a kinase scaffold protein and as a dynamic regulator of the beta2-adrenergic receptor complex. However, the biological role of AKAP12 in cancer development is not well understood. The AKAP12 gene encodes two major isoforms of 305 and 287 kDa (designated AKAP12A and AKAP12B, respectively, in this report). We found that these two isoforms are independently expressed and that they are probably under the control of two different promoters. Moreover, both isoforms were absent from the majority of human gastric cancer cells. The results from methylation-specific PCR (MSP) and bisulfite sequencing revealed that the 5' CpG islands of both AKAP12A and AKAP12B are frequently hypermethylated in gastric cancer cells. Treatment with DNA methyltransferase inhibitor and/or histone deacetylase inhibitor efficiently restored the expression of AKAP12 isoforms, confirming that DNA methylation is directly involved in the transcriptional silencing of AKAP12 in gastric cancer cells. Hypermethylation of AKAP12A CpG island was also detected in 56% (10 of 18) of primary gastric tumors. The restoration of AKAP12A in AKAP12-nonexpressing cells reduced colony formation and induced apoptotic cell death. In conclusion, our results suggest that AKAP12A may function as an important negative regulator of the survival pathway in human gastric cancer.


Assuntos
Proteínas de Ciclo Celular/genética , Mitógenos/genética , Neoplasias Gástricas/genética , Proteínas de Ancoragem à Quinase A , Sequência de Bases , Proteínas de Ciclo Celular/antagonistas & inibidores , Divisão Celular/genética , Linhagem Celular , Linhagem Celular Tumoral , Primers do DNA , Humanos , Mitógenos/antagonistas & inibidores , Dados de Sequência Molecular , Isoformas de Proteínas/antagonistas & inibidores , Isoformas de Proteínas/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Neoplasias Gástricas/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...